Abstract
As a glycol-protein located in extracellular matrix (ECM), tenascin-C (TNC) is absent in most normal adult tissues but is highly expressed in the majority of malignant solid tumors. Pancreatic cancer is characterized by an abundant fibrous tissue rich in TNC. Although it was reported that TNC’s expression increased in the progression from low-grade precursor lesions to invasive cancer and was associated with tumor differentiation in human pancreatic cancer, studies on the relations between TNC and tumor progression in pancreatic cancer were rare. In this study, we performed an analysis to determine the effects of TNC on modulating cell apoptosis and chemo-resistance and explored its mechanisms involving activation in pancreatic cancer cell. The expressions of TNC, ERK1/2/p-ERK1/2, Bcl-xL and Bcl-2 were detected by immunohistochemistry and western blotting. Then the effects of exogenous and endogenous TNC on the regulation of tumor proliferation, apoptosis and gemcitabine cytotoxicity were investigated. The associations among the TNC knockdown, TNC stimulation and expressions of ERK1/2/NF-κB/p65 and apoptotic regulatory proteins were also analyzed in cell lines. The mechanism of TNC on modulating cancer cell apoptosis and drug resistant through activation of ERK1/2/NF-κB/p65 signals was evaluated. The effect of TNC on regulating cell cycle distribution was also tested. TNC, ERK1/2/p-ERK1/2, and apoptotic regulatory proteins Bcl-xL and Bcl-2 were highly expressed in human pancreatic cancer tissues. In vitro, exogenous TNC promoted pancreatic cancer cell growth also mediates basal as well as starved and drug-induced apoptosis in pancreatic cancer cells. The effects of TNC on anti-apoptosis were induced by the activation state of ERK1/2/NF-κB/p65 signals in pancreatic cell. TNC phosphorylate ERK1/2 to induce NF-κB/p65 nucleus translocation. The latter contributes to promote Bcl-xL, Bcl-2 protein expressions and reduce caspase activity, which inhibit cell apoptotic processes. TNC mediated gemcitabine chemo-resistance via modulating cell apoptosis in pancreatic cancer. TNC resulted in the enrichment of pancreatic cancer cells in S-phase with a concomitant decrease in number of cells in G1 phase. The present study indicated TNC in cellular matrix induces an activation of ERK1/2/NF-κB/p65 signaling cascade and thereby mediates resistance to apoptosis in pancreatic cancer. TNC could serve as a diagnostic marker and predictor of gemcitabine response and potentially as a target for chemotherapy of pancreatic cancer.
Similar content being viewed by others
References
Siegel Rebecca, Naishadham Deepa, Jemal Ahmedin (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
Stathis Anastasios, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172
Schneider G, Siveke JT, Eckel F, Schmid RM (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128:1606–1625
Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29:179–187
Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128:907–921
Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA (1993) The pancreas: biology, pathobiology and disease. Raven, New York
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mousemodel of pancreatic cancer. Science 324:1457–1461
Omary MB, Lugea A, Lowe AW, Pandol SJ (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117:50–59
Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163
Orend G, Saupe F, Schwenzer A, Midwood K (2014) The extracellular matrix and cancer: regulation of tumor cell biology by tenascin-C. iConcept, Hong Kong
Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C (2004) Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 57:1151–1155
Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, Schirmacher P (2006) Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208:673–685
Jones PL, Jones FS (2000) Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19:581–596
Paron I, Berchtold S, Vörös J, Shamarla M, Erkan M, Höfler H, Esposito I (2011) Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 6:e21684
Fryer BH, Field J (2005) Rho, rac, pak and angiogenesisold roles and newly identified responsibilities in endothelial cells. Cancer Lett 229:13–23
Jones PL, Crack J, Rabinovitch M (1997) Regulation of Tenascin-C, a vascular smooth muscle cell survival factor that interacts with the αvβ3 integrin to promote epidermal growth. J Cell Biol 139:279–293
Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200:488–499
Mettouchi A, Cabon F, Montreau N, Dejong V, Vernier P, Gherzi R, Mercier G, Binétruy B (1997) The c-Jun-induced transformation process involves complex regulation of tenascin-C expression. Mol Cell Biol 17:3202–3209
Iyer AK, Tran KT, Griffith L, Wells A (2008) Cell surface restriction of EGFR by a tenascin cytotactin-encoded egf-like repeat is preferential for motility-related signaling. J Cell Physiol 214:504–512
Kim SO, Kim MR (2013) Gingerol prevents disassembly of cell junctions and activities of MMPs in invasive human pancreas cancer cells through ERK1/2/ NF-κB/Snail signal transduction pathway. Evid Based Complement Alternat Med 2013:761852
Rengifo-Cam W, Umar S, Sarkar S, Singh P (2007) Antiapoptotic effects of progastrin on pancreatic cancer cells are mediated by sustained activation of nuclear factor-κB. Cancer Res 67:7266–7274
Cheng Y, Diao DM, Zhang H, Song YC, Dang CX (2013) Proliferation enhanced by NGF-NTRK1 signaling makes pancreatic cancer cells more sensitive to 2DG-induced apoptosis. Int J Med Sci 10:634–640
Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F, Yu VC, Kwok RP, Opipari AW, Castle VP (2006) Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 8:964–974
Tod J, Jenei V, Thomas G, Fine D (2013) Tumor-stromal interactions in pancreatic cancer. Pancreatology 13:1–7
Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485–495
Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12:1794–1803
Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ (2003) Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88:1963–1970
Adams JM, Cory S (1998) The Bcl-2 protein family: arbiter of cellsurvival. Science 281:1322–1326
Westphal S, Kalthoff H (2003) Apoptosis: targets in pancreatic cancer. Mol Cancer 7:2–6
Ruvolo PP, Deng X, May WS (2001) Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15:515–522
Chen W, Li Z, Bai L, Lin Y (2011) NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed) 16:1172–1185
Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808–1812
Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936–2943
Acknowledgments
This study was funded by National Natural Fund (31370861) and Tianjin Basic Research Plan Project (13JCZDJC31300). The authors declare that they have no conflict of interest. We thank Tianjin Medical University Cancer Institute and Hospital for providing human pancreatic adenocarcinoma samples and for all expert discussions. We thank Dwayne Stupack (University of California, San Diego, USA) for giving helpful advice during the course of our study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shi, M., He, X., Wei, W. et al. Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-κB pathway. Apoptosis 20, 843–857 (2015). https://doi.org/10.1007/s10495-015-1106-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-015-1106-4